Nonclinical development strategies for gene therapies are unique from other modalities. The European Federation of Pharmaceutical Industries and Associates (EFPIA) Gene Therapy Working Group surveyed EFPIA member and nonmember pharmaceutical and biotechnology companies about their current practices for designing and implementing nonclinical toxicology studies to support the development of viral vector-delivered in vivo gene therapies. Compiled responses from 17 companies indicated that these studies had some variability in species selection, study design elements, biodistribution, immunogenicity or genomic insertion assessments, safety pharmacology and regulatory interactions. Although there was some consistency in general practice, there were examples of extreme case-by-case differences. The variability in responses are discussed herein. Key development challenges were also identified. Results from this survey emphasize the importance for harmonization of regulatory guidelines for the development of gene therapy products, while still allowing for case-by-case flexibility in nonclinical toxicology studies. However, the appropriate timing for a harmonized guidance, particularly with a platform that continues to rapidly evolve, remains in question.
The publication appeared in August 31st online issue of Mol Ther Meth Clin Dev (https://www.cell.com/action/showPdf?pii=S2329-0501%2820%2930183-2)
